Home / About
Metanoia is an ancient Greek word for a deep change of mind, heart, and way of being. It's our name and our purpose.
Not treating illness. Expanding potential.
Metanoia advances the science of natural psychedelics for personal growth and human flourishing in healthy adults. We work through multidisciplinary research, integrating genetics, chemistry, neuroscience, cultivation, therapy, and sex- and gender-based differences into a 360° understanding, to ask whether, and under what conditions, these substances affect the dimensions that shape a life: creativity, problem-solving, emotional resilience, perception, empathy, and social connection, and to report what the evidence does and does not yet show. Alongside research, we build free, science-based public education so this knowledge reaches everyone.
A world where decisions about natural psychedelics, by individuals and by policymakers, rest on evidence that is public, verified, and honest about its limits.
Why Now
After decades in the margins, psychedelic science is having its most consequential moment. Metanoia's job is to translate that moment honestly, and to ask what it means not for illness, but for growth.
Randomised trials of psilocybin have reported results in leading journals, some positive and some inconclusive, and in April 2026 an executive order directed federal agencies to prioritise review of, and create access pathways for, psychedelic drugs for serious mental illness. The evidence is real, still debated, and evolving month to month.
Mertens LJ et al., JAMA Psychiatry 83(5):448-460, 2026 · PMID 41848690 · DOI · Level 1, phase 2b randomised trial in treatment-resistant depression (144 participants) that did not meet its primary endpoint. Full text read on PubMed Central 2 October 2026. Executive Order 14401, Accelerating Medical Treatments for Serious Mental Illness, signed 18 April 2026, 91 FR 21709, document 2026-07907 · Federal Register · Level 1. Text read in full 2 October 2026.
In a 2023 survey in Canada, the United States, Australia and New Zealand, about one in five respondents reported ever using psilocybin, LSD, MDMA or ketamine. Among them, an estimated 10 to 20% had asked a medical provider about medical use, and over a third of past-year users reported an adverse health effect. People are already using these substances. Reliable, science-based guidance has not kept pace.
Graham M et al., International Journal on Drug Policy 154:105348, 2026 · PMID 42247761 · DOI · Level 1, cross-sectional survey. Abstract checked on PubMed 23 September 2026.
Nearly all of this research targets diagnosed illness. The everyday, healthy person seeking growth, creativity, or self-understanding sits almost entirely outside the studies, and outside the safeguards. That gap is why Metanoia exists, and it is what our research agenda is built to close.
Metanoia focus area · see our research agenda.
Today, Metanoia is one thing: a California 501(c)(3) public charity. That is the entire organization: there is no affiliate, no subsidiary, and no commercial arm, and Metanoia is not party to any agreement with any such entity.
Our long-term plan is a hybrid structure, and we would rather describe it now than surprise anyone with it later. The reasoning is simple. A charity is the right home for research direction, public education, governance, and donor-funded work, but it is a poor instrument for raising investment capital or carrying long, expensive research. A separate for-profit research affiliate, limited in scope to contracted institutional research, could do that second job. No such affiliate has been formed, and no decision has been made about when, where, or whether to form one.
Our board has also stated, openly, that it may in the future set incentives for whoever leads such an affiliate, potentially including a small equity stake for our founder. Any such step would first require independent-committee review, a fair-market valuation, a cap kept below the federal "disqualified person" threshold, disclosure on our public Form 990, and the founder's abstention from the vote, approved only by a supermajority of the full board after legal and jurisdictional review. No affiliate exists today, no incentive has been proposed, and no equity has been granted.
If and when such an affiliate is formed, the two entities would keep separate boards and separate finances, and all public-facing education and all fundraising would continue to benefit the nonprofit mission. We will update this page the day anything about that changes.
Why you won't find our faces here
You will notice that this website names no personalities and shows no team photographs. That is a deliberate choice, and we think it matters enough to explain.
The psychedelic field has too often been shaped by charismatic figures: gurus, celebrities, founders with a story to sell. We are building the opposite: an organization whose credibility rests entirely on the quality and honesty of its work, not on the reputation of any individual. Our book, our research, and our sources are all open for anyone to check. That is where trust should come from.
Staying lean and quiet is also practical. A mission-first organization that spends nothing on profile-building is one where more of every donated dollar reaches the actual work, the research, the free education, the tools we're building for the public.
This is not permanent secrecy. As Metanoia matures, we will convene an advisory board of scientists, ethicists, and practitioners, and we will introduce them properly when they are in place. Until then, we would rather be judged by what we produce than by who we are. Where others ask "how do we treat what's broken?" we ask "how do we unlock what's possible?", and we would rather you remember the question than remember us.
The team at MetanoiaEarly supporters help shape our scientific goals, protocols, and direction. Join us now.